UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/758,495	01/15/2004	James H. Silver	JSILVER.ICP2CP	6182	
20995 KNOBBE MA	7590 01/23/2001 RTENS OLSON & BEA		EXAMINER		
2040 MAIN STREET			NASSER, ROBERT L		
FOURTEENTH FLOOR IRVINE, CA 92614		•	ART UNIT	PAPER NUMBER	
,			3735		
•	•		NOTIFICATION DATE	DELIVERY MODE	
•			01/23/2007	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jcartee@kmob.com eOAPilot@kmob.com

Supplemental Notice of Allowability Application No. 10/758,495 Examiner Art Unit Robert L. Nasser 3735

	Robert L. Nasser	3735	
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commu IGHTS . This application is s	this application. If not inc	cluded due course. THIS
1. This communication is responsive to communication filed:	<u>1/3/2007</u> .		
2. ⊠ The allowed claim(s) is/are <u>55-80</u> .	•		
3.	e been received. e been received in Application cuments have been received of this communication to file MENT of this application. hitted. Note the attached EXA es reason(s) why the oath or st be submitted. son's Patent Drawing Review s Amendment / Comment or .84(c)) should be written on the the header according to 37 CF sit of BIOLOGICAL MATE	n No I in this national stage appliant this national stage appliant in the matter of the declaration is deficient. If (PTO-948) attached in the Office action of the drawings in the front (no R 1.121(d)). ERIAL must be submitted.	e requirements or NOTICE OF
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	6. ☐ Interview Su Paper No./I 7. ☑ Examiner's	ormal Patent Application immary (PTO-413), Mail Date Amendment/Comment	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's	Statement of Reasons for	Allowance
	•		

Art Unit: 3735

The examiner is re-issuing this notice of allowance in response to applicant's broadened definition of a metabolic product of nitric oxide filed 1/3/2007

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In paragraph [0001] of the specification, in line 2, after August 9, 2002, the following has been added: -- now US Patent 7006858 --

In paragraph [0001] of the specification, line 3, after November 8, 2001, the following has been added: -- now US patent 7033322 --.

The following is an examiner's statement of reasons for allowance: Claims 55-80 define over the art of record in that none of the art has a sensor on a support, with a layer that minimizes the formation of thrombus, where the sensor detects a metabolic product of nitric oxide. Applicant has not explicitly limited this term in the specification. However, it is the examiner's position that the term would be understood by one skilled in the art. Publication 2003/0136673 states that nitric oxide is converted in the body to nitrate, nitrite, and S-nitrothiol. In addition, applicant has stated that the term includes

Art Unit: 3735

peroxynitrite, nitrotyrosine and nitrosyl hemoglobin. Accordingly, the term "metabolic product of nitric oxide is being limited to nitrate, nitirite, S-nitrothiol, peroxynitrite, nitrotyrosine and nitrosyl hemoglobin.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert L. Nasser whose telephone number is 571 272-4731. The examiner can normally be reached on m-f 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Charles Marmor II can be reached on 571 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3735

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Robert L. Nasser Primary Examiner Art Unit 3735

RLN January 9, 2007 Red 8 Many